Stay updated on GLP-1 Agonist and Albuminuria in Type 2 Diabetes Clinical Trial
Sign up to get notified when there's something new on the GLP-1 Agonist and Albuminuria in Type 2 Diabetes Clinical Trial page.

Latest updates to the GLP-1 Agonist and Albuminuria in Type 2 Diabetes Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedThe page header now shows Revision: v3.4.2, replacing the previous Revision: v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check20 days agoChange DetectedSite revision updated from v3.4.0 to v3.4.1. No changes to study content or data are visible.SummaryDifference0.1%

- Check27 days agoChange DetectedShow glossary was added, and metadata labels were updated (Last Update Submitted that Met QC Criteria; No FEAR Act Data) with the revision/version updated to v3.4.0, replacing the previous v3.3.4 label. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check42 days agoChange DetectedThe page revision was updated to v3.3.4, representing a minor metadata update that does not affect the study information shown. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check63 days agoChange DetectedLocations now includes New York; HHS Vulnerability Disclosure and New York Locations were removed. Page revision updated to v3.3.3.SummaryDifference0.2%

- Check92 days agoChange DetectedPage revision updated from v3.2.0 to v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to GLP-1 Agonist and Albuminuria in Type 2 Diabetes Clinical Trial
Enter your email address, and we'll notify you when there's something new on the GLP-1 Agonist and Albuminuria in Type 2 Diabetes Clinical Trial page.